ECO Animal Health receive marketing authorisation for swine vaccine

ECO Animal Health Group plc (LON:EAH) has announced that it has received a marketing authorisation from Brazil’s Ministry of Agriculture, Livestock and Food Supply for Circo/MycoGard®, a vaccine for swine.

Circo/MycoGard® is used for the vaccination of healthy piglets against Porcine Circovirus type 2 and Mycoplasma hyopneumoniae, two of the most common primary pig respiratory disease pathogens affecting the health and productivity of swine globally.

This marketing authorisation is the first licence obtained by ECO-Pharm Limited, a joint venture established in the Republic of Ireland in 2018 between ECO Animal Health Ltd, a wholly owned subsidiary of the Group, and Pharmgate Corp of Wilmington, North Carolina, USA responsible for the registration, marketing, sale and distribution of a number of Pharmgate LLC swine vaccine products.

Marc Loomes, CEO said: “Brazil is a globally important swine market which is reaching record pork export levels.  This first vaccine marketing authorisation in Brazil marks a significant milestone as we build our capability with vaccines and broaden our product portfolio. The speed with which Circo/MycoGard® was approved in Brazil under difficult circumstances is most gratifying and a credit to the team.”

Colin Gray, President and CEO of Pharmgate commented: “Our joint international efforts are vitally important to the long term growth of our companies. I am very pleased with our teams and the work they have accomplished in getting our first vaccine into this highly important market. I look forward to similar success over the coming months and years.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
ECO Animal Health Group plc

More articles like this

ECO Animal Health Group plc

ECO Animal Health ECOVAXXIN® trademark approved by the EU

ECO Animal Health Group plc (LON:EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, has announced that the ECOVAXXIN® trademark has been approved by the European

ECO Animal Health Group plc

ECO Animal Health completes sale of freehold properties

ECO Animal Health Group plc (LON:EAH) has announced that on 5 January 2024 the Company completed the sale of its freehold property in New Malden, Surrey.  This was the former registered office of the Company and following

ECO Animal Health Group plc

ECO Animal Health to host two Capital Markets events

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that it will be hosting two Capital Markets events focused on progress and

ECO Animal Health Group plc

ECO Animal Health Group Retail Investor Presentation

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, will be hosting a Capital Markets Day presentation for retail investors focusing on progress

ECO Animal Health Group plc

ECO Animal Health AGM to be held on Thursday 7 September 2023

ECO Animal Health Group plc (LON:EAH), a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, has announced that the Company is today posting to shareholders notice of the Company’s Annual

ECO Animal Health Group plc

ECO Animal Health Group revenue ahead of market expectations

ECO Animal Health Group plc (LON:EAH) have today provided final results for the year ended 31 March 2023. HIGHLIGHTS Financial ·      Revenue and adjusted EBITDA ahead of market expectations ·      Group sales increased by 4% to £85.3m, driven primarily